Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27097799 | 1.00 | NR1H2 (0.43) | NR1H2PRMT5WDR77PDE4DPDE4A | |
| SCHEMBL27097864 | 0.94 | NR1H2 (0.43) | NR1H2PRMT5WDR77PDE4DPDE4A | |
| SCHEMBL26495742 | 0.94 | NR1H2 (0.43) | NR1H2PRMT5WDR77PDE4DPDE4A | |
| SCHEMBL20129252 | 0.94 | NR1H2 (0.43) | NR1H2PRMT5WDR77PDE4DPDE4A | |
| SCHEMBL20129179 | 0.94 | NR1H2 (0.48) | NR1H2PRMT5WDR77PDE4DPDE4A | |
| SCHEMBL20128969 | 0.93 | NR1H2 (0.43) | NR1H2PRMT5WDR77PDE4DPDE4A | |
| SCHEMBL26048944 | 0.90 | NR1H2 (0.47) | NR1H2PRMT5WDR77PDE4DPDE4A | |
| SCHEMBL20129035 | 0.89 | NR1H2 (0.47) | NR1H2PRMT5WDR77PDE4BGPR119 | |
| SCHEMBL20129254 | 0.89 | NR1H2 (0.47) | NR1H2PRMT5WDR77PDE4BGPR119 | |
| SCHEMBL20129039 | 0.86 | NR1H2 (0.45) | NR1H2PRMT5WDR77GPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | NR1H2 3409/4885PRMT5 584/4885WDR77 1631/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | NR1H2 3751/4885PRMT5 547/4885WDR77 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.